Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules [Yahoo! Finance]